Good evening :)
$
₹
Merck & Company Inc

Merck & Company Inc

MRK

NYSE
Asset Logo

Merck & Company Inc

MRK

NYSE
$152.321.30% (+1.96)
$
₹
$152.321.30% (+1.96)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - General

Mega Cap

With a market cap of $356.9B the stock is ranked 33

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

149.14
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

8.72
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$0.97
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

2.79
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

3.64%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

2.26%

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 28 analysts reports

Buy
19 analysts
Hold
9 analysts
Sell
0 analyst

Price Upside

+6.61%

Earnings Growth

-69.14%

Rev. Growth

+3.5%

See Detailed Forecast

Company Profile

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
45.78
45.78
1Y Return
56.59%
56.59%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
40.39
40.39
1Y Return
48.81%
48.81%
Buy Reco %
69.56
69.56
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
30.39
30.39
1Y Return
31.97%
31.97%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
26.00
26.00
1Y Return
11.26%
11.26%
Buy Reco %
75.00
75.00
Novo Nordisk A/S
NVO
Novo Nordisk A/S
P/E Ratio
9.89
9.89
1Y Return
12.58%
12.58%
Buy Reco %
21.42
21.42
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 6.61% growth, versus a trailing 3-year CAGR of 15.33%.

2026
Current$150.36Baseline
Analyst Target - 1 year
Target$160.29+6.61%

All values in $

202220232024202520262027$109.35$131.67$154.00Target+6.61%
2026
Current$150.36Baseline
Analyst Target - 1 year
Target$160.29+6.61%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 3.50% growth, versus a trailing 3-year CAGR of 3.08%.

2025
Current$64.92Baseline
Forecast for Dec 2026
High$67.75+4.35%
Average$67.19+3.5%
Low$66.83+2.94%

All values in $ Billion

20212022202320242025202648.7059.2860.1164.1664.92Low+2.94%Average+3.5%High+4.35%
2025
Current$64.92Baseline
Forecast for Dec 2026
High$67.75+4.35%
Average$67.19+3.5%
Low$66.83+2.94%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

Lower earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -69.14% growth, versus a trailing 3-year CAGR of 6.24%.

2025
Current$8.97Baseline
Forecast for Dec 2026
High$2.99-66.67%
Average$2.77-69.14%
Low$2.5-72.13%

All values in $

2021202220232024202520266.267.481.57.648.97Low-72.13%Average-69.14%High-66.67%
2025
Current$8.97Baseline
Forecast for Dec 2026
High$2.99-66.67%
Average$2.77-69.14%
Low$2.5-72.13%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

16.3
2.9
16.2
-4.2
16.6
-1.3
18
5
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue16.1116.6515.6215.6115.817.1816.3216.2816.6018.08
Net Income5.453.153.745.074.425.782.96-4.24-1.335.06
Net Profit Margin33.85%18.95%23.95%32.51%28.01%33.66%18.15%-26.03%-8.03%28.00%
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - General

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Merck & Company Inc 149.148.722.79
Eli Lilly and Company45.7831.351.35
Johnson & Johnson40.397.983.04
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare MRK with any stock or ETF
Compare MRK with any stock or ETF
Comparing from
MRK
LLY
JNJ
Loading...

Frequently asked questions

  1. Merck & Company Inc (MRK) share price today is $152.32 as of November 5, 2026 at 8:26 PM IST. The stock touched a day high of $152.37 and a day low of $150.83.

  2. Merck & Company Inc stock trades on NYSE under the ticker symbol MRK.

  3. Merck & Company Inc's market capitalization is $356.92B as of November 5, 2026 at 8:26 PM IST.

  4. Merck & Company Inc's price-to-earnings (P/E) ratio is 149.14 as of November 5, 2026.

  5. Merck & Company Inc's price-to-book (P/B) ratio is 8.72 as of November 5, 2026.

  6. Yes, Merck & Company Inc pays a dividend, with a current dividend yield of 2.26%.

  7. Yes, You can buy Merck & Company Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy Merck & Company Inc shares in three steps: 1. Search Merck & Company Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since Merck & Company Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in Merck & Company Inc (MRK) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0656 shares at the current price of $152.32.

Loading...